Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

References for PMC Articles for PubMed (Select 21978456)

1.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M.

Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.

PMID:
21741824
2.

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

Calabrò L, Danielli R, Sigalotti L, Maio M.

Semin Oncol. 2010 Oct;37(5):460-7. doi: 10.1053/j.seminoncol.2010.09.006. Review.

PMID:
21074061
3.

Anti-CTLA-4 antibody adjuvant therapy in melanoma.

Eggermont AM, Testori A, Maio M, Robert C.

Semin Oncol. 2010 Oct;37(5):455-9. doi: 10.1053/j.seminoncol.2010.09.009. Review.

PMID:
21074060
4.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L.

J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. Erratum in: J Clin Oncol. 2012 Feb 20;30(6):679. J Clin Oncol. 2010 Nov 10;28(32):4868.

5.

Targeting breast cancer stem cells.

Liu S, Wicha MS.

J Clin Oncol. 2010 Sep 1;28(25):4006-12. doi: 10.1200/JCO.2009.27.5388. Epub 2010 May 24. Review.

PMID:
20498387
6.

A gene expression signature identifies two prognostic subgroups of basal breast cancer.

Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, Viens P, Birnbaum D, Bertucci F.

Breast Cancer Res Treat. 2011 Apr;126(2):407-20. doi: 10.1007/s10549-010-0897-9. Epub 2010 May 21.

PMID:
20490655
7.

Breast cancer molecular profiling with single sample predictors: a retrospective analysis.

Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS.

Lancet Oncol. 2010 Apr;11(4):339-49. doi: 10.1016/S1470-2045(10)70008-5. Epub 2010 Feb 22.

8.

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS.

J Clin Invest. 2010 Feb;120(2):485-97. doi: 10.1172/JCI39397. Epub 2010 Jan 4.

9.

Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.

Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A.

Eur J Cancer. 2010 Feb;46(3):549-57. doi: 10.1016/j.ejca.2009.11.020. Epub 2009 Dec 18.

PMID:
20022486
10.

Histological and molecular types of breast cancer: is there a unifying taxonomy?

Weigelt B, Reis-Filho JS.

Nat Rev Clin Oncol. 2009 Dec;6(12):718-30. doi: 10.1038/nrclinonc.2009.166. Review.

PMID:
19942925
11.

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G.

J Clin Oncol. 2010 Jan 1;28(1):105-13. doi: 10.1200/JCO.2009.23.7370. Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.

12.

Triple-negative breast cancer--current status and future directions.

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N.

Ann Oncol. 2009 Dec;20(12):1913-27. doi: 10.1093/annonc/mdp492. Epub 2009 Nov 9. Review.

13.

Use of archived specimens in evaluation of prognostic and predictive biomarkers.

Simon RM, Paik S, Hayes DF.

J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.

14.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3.

15.

Mammary development meets cancer genomics.

Prat A, Perou CM.

Nat Med. 2009 Aug;15(8):842-4. doi: 10.1038/nm0809-842. No abstract available.

PMID:
19661985
16.

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.

Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Apr;120(3):567-79. doi: 10.1007/s10549-009-0416-z. Epub 2009 May 20.

PMID:
19455418
17.

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB.

Cancer Res. 2009 May 15;69(10):4116-24. doi: 10.1158/0008-5472.CAN-08-3441. Epub 2009 May 12.

18.

Genomic grade index is associated with response to chemotherapy in patients with breast cancer.

Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L.

J Clin Oncol. 2009 Jul 1;27(19):3185-91. doi: 10.1200/JCO.2008.18.5934. Epub 2009 Apr 13.

19.

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO.

Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24.

20.

A compact VEGF signature associated with distant metastases and poor outcomes.

Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM.

BMC Med. 2009 Mar 16;7:9. doi: 10.1186/1741-7015-7-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk